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Innate-like T cells such as invariant natural killer T (iNKT) cells and mucosal-associated 
T (MAIT) cells, characterized by a semi-invariant T cell receptor and restriction toward 
MHC-like molecules (CD1 and MR1 respectively), are a unique unconventional immune 
subset acting at the interface of innate and adaptive immunity. Highly represented at 
barrier sites and capable of rapidly producing substantial amounts of cytokines, they 
serve a pivotal role as first-line responders against microbial infections. In contrast, 
it was demonstrated that innate-like T  cells can be skewed toward a predominant 
pro-inflammatory state and are consequently involved in a number of autoimmune and 
inflammatory diseases like inflammatory bowel diseases and rheumatic disorders, such 
as spondyloarthritis (SpA) and rheumatoid arthritis. Interestingly, there is link between gut 
and joint disease as they often co-incide and share certain aspects of the pathogenesis 
such as established genetic risk factors, a critical role for pro-inflammatory cytokines, 
such as TNF-α, IL-23, and IL-17 and therapeutic susceptibility. In this regard dysreg-
ulated IL-23/IL-17 responses appear to be crucial in both debilitating pathologies and 
innate-like T cells likely act as key player. In this review, we will explore the remarkable 
features of iNKT cells and MAIT cells, and discuss their contribution to immunity and 
combined gut–joint disease.
Keywords: innate-like T cells, invariant natural killer T cells, mucosal-associated invariant T cells, CD1, MR1, 
rheumatic diseases, inflammatory bowel disease, gut–joint axis
inTRODUCTiOn
Over the past decades, innate-like T  cells have gained increasing attention given their unique 
biology and potential involvement in multiple immune and inflammatory diseases. Those cells, 
with overlapping features of both the innate and adaptive immune system, are characterized by an 
antigen-specific semi-invariant T cell receptor (TCR) with restricted V(D)J rearrangement. Innate-
like T cells are able to rapidly produce cytokines, which makes them an ideal first-line defense against 
microbial infections (1). However, it has become clear that these cells show functional plasticity and 
can be skewed toward a more pro-inflammatory state (2). Two members of this unconventional 
T  cell population are invariant natural killer T (iNKT) cells and mucosal-associated invariant 
T (MAIT) cells. Both cell types have the unique feature of recognizing atypical non-peptide antigens 
presented by highly conserved MHC-related molecules, respectively CD1 and MR1. iNKT  cells 
respond to glycolipid molecules, whereas MAIT cells can be activated by vitamin B2 (riboflavin) 
metabolites, which are intermediates from bacterial and yeast biosynthetic pathways (3). Gamma 
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delta (γδ) T cells are a third innate-like T cell population (4), but 
the focus here will be on CD1- and MR1-restricted T cells. In this 
review, we want to highlight the intriguing nature of these cells 
and discuss what is known about their role in rheumatic diseases 
like spondyloarthritis (SpA) and rheumatoid arthritis (RA), next 
to inflammatory bowel diseases (IBD).
Spondyloarthritides are a group of chronic inflammatory 
disorders that primarily affect the musculoskeletal system and are 
multifactorial in origin. Some subtypes affect mainly the axial joints 
(spine and sacroiliac joints), with ankylosing spondylitis (AS) as 
prototypical disease, while others have a more peripheral manifesta-
tion (arthritis of the limbs and enthesitis) (5). RA, another chronic 
rheumatic disorder, has an autoimmune basis and is characterized 
by the presence of autoantibodies direct against i.a. citrullinated 
antigens (6). Most commonly involved are the small joints of hands 
and feet, often with a symmetrical distribution, whereas in SpA joint 
inflammation is generally non-symmetrical. IBD is the collective 
term for a group of inflammatory diseases of the digestive tract, 
leading to gastrointestinal complaints. The two best known subtypes 
are Crohn’s disease (CD) and ulcerative colitis (UC) (7).
Remarkably, SpA often is accompanied by extra-articular 
manifestations, such as acute anterior uveitis, psoriasis, or IBD. 
Histological evaluation showed that about 50% of SpA patients 
without gastrointestinal symptoms have microscopic intestinal 
inflammation (8), of which a fraction (5–10%) develops CD over 
time (8, 9). Furthermore the presence of subclinical gut inflamma-
tion is associated with shifts in the composition of the gut micro-
biome (10–12). A state of intestinal dysbiosis has also observed 
in RA and IBD patients (6, 11, 13–15). Additionally in RA, there 
is a significant correlation with periodontitis and the presence of 
Porphyromonas gingivalis in the oral cavity. This bacterium could 
play an important role in the pathogenesis of RA through citrul-
lination of proteins using a specific enzyme (peptidyl arginine 
deiminase), potentially leading to the production of anti-cyclic 
citrullinated peptide (anti-CCP) autoantibodies relevant to RA 
disease (16, 17). This finding underscores that microorganisms 
can have a direct pathological role in disease pathogenesis. On the 
other hand, alterations in microbial composition can also play an 
indirect role by modulation of specific immune cell functions rel-
evant for these diseases. Hence, the ability of recognizing bacterial 
antigens (or derived products) combined with their clear presence 
at barrier sites, makes innate-like T cells an appealing target to 
study in the context of the gut–joint axis in rheumatic diseases.
A crucial role for pro-inflammatory cytokines in the patho-
genesis of SpA, RA, and IBD, is confirmed by current knowledge 
from genome-wide association studies (GWAS) and anti-cytokine 
trials. Interestingly, SpA, RA, and IBD share clinical responsive-
ness to anti-tumor necrosis factor (TNF)-α therapy but sig-
nificantly differ in their response toward inhibition of other key 
inflammatory cytokines like IL-17. Over the years, the interleukin 
(IL)-23/IL-17 immune axis has manifested as a major player in the 
pathogenesis of SpA (18). GWAS studies have revealed polymor-
phisms in the IL23R gene associated with both SpA and IBD (19). 
Furthermore, there is extensive evidence from in  vivo models, 
translational studies, and clinical trials (2, 20–22). Curiously, 
anti-IL-17 treatment was not effective in patients with RA or IBD 
with some reports even suggesting a worsening of IBD, which 
might be linked to an effect on barrier integrity (23–25). IL-23 is 
essential for the terminal differentiation and inflammatory func-
tions of T helper-17 (Th17) cells. Interestingly, it has been shown 
that also innate-like T  cells express the key Th17 transcription 
factor retinoic acid receptor-related orphan receptor-γt (RORγt) 
and that they can respond toward IL-23 by producing IL-17 and 
related cytokines like IL-22 (22). The importance of this finding 
was underscored by a mouse study, in which IL-23 overexpres-
sion (an SpA-like model using minicircle DNA technology) could 
induce enthesitis independent of conventional Th17 cells (26). As 
disease induction did require the presence of CD4−CD8− T cells, 
there could be a role for IL-23 responsive innate-like T cells (27).
inKT CeLLS
Biology and Localization
Invariant natural killer T  cells are CD1d-restricted T  cells 
which express a semi-invariant TCR consisting of an invariant 
α chain [in particular, the variable (V) and joining (J) segments 
Vα14–Jα18 in mice and Vα24–Jα18 in humans], combined with 
a restricted β chain repertoire, usually Vβ2, Vβ7, or Vβ8.2 in mice 
and Vβ11 in humans (28, 29). Identification of these cells in mice 
can be performed by the use of CD1d tetramers and in humans 
by using CD1d tetramers, a specific Vα24Jα18 Ab (clone 6B11) 
or the combination of anti-Vα24 and anti-Vβ11 antibodies. 
In contrast to conventional T cells which detect self or foreign 
peptide antigen–MHC complexes, iNKT cells recognize only gly-
colipid antigens bound to CD1d, a MHC class I-like glycoprotein 
(30). Currently, identified antigens are predominantly of non- 
mammalian nature, with α-galactosylceramide (α-GalCer) as the 
most potent and best studied example. However, also microbial 
derived (31) and endogenous ligands have been described (28, 32, 
33). Of note, the human genome encodes five CD1 genes (CD1a, 
b, c, d, and e) whereas only CD1d is expressed in mice, and human 
CD1a, b, and c restricted T cells have been described too (34).
A hallmark of iNKT cell biology is the ability to secrete large 
amounts of cytokines and chemokines upon TCR recognition of 
lipid antigen–CD1 complexes or via indirect (TCR independent, 
mainly cytokine driven) stimulation, hereby acting as a “bridge” 
between innate and adaptive immune responses (35, 36). In anal-
ogy to classification of conventional T cells based on their cytokine 
production, iNKT cells can be subdivided in NKT1, NKT2, and 
NKT17 cells (37). Each of these subsets expresses distinct tran-
scription factors which correlate with their capacity to secrete spe-
cific cytokines. NKT1 cells are T box transcription factor TBX21 
(T-bet) positive and primarily secrete interferon (IFN)-γ, NKT2 
cells express high levels of GATA-binding protein 3 (GATA3) and 
promyelocytic leukemia zinc finger protein (PLZF), and produce 
IL-4 and IL-13, and NKT17 cells express RORγt next to inter-
mediate levels of PLZF and produce IL-17 as signature cytokine 
(38–40). All these subsets acquire their functional capacity during 
the development in the thymus and are distributed to the peripheral 
organs in a tissue-specific manner (41). However, there are also 
reports suggesting that peripheral iNKT cells are able to further 
functionally differentiate under inflammatory conditions (42, 43). 
In addition, it is also clear that iNKT cells experience further 
3
Mortier et al. Innate-Like T Cells in Spondyloarthritis
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1489
maturation at mucosal surfaces (e.g., lung and gut) as evidenced 
from experiments with germ-free mice (44, 45).
Finally, next to above-mentioned subsets, also other particular 
iNKT  cells, such as NKTreg (FOXP3+) (46), NKTFH (CXCR5+ 
PD-1hi) (47), NKT10 cells (48), and adipose tissue residing iNKT 
(PLZF-E4BP4+) cells (49) have been described and warrant 
further investigation. The frequency of iNKT cells in mice is sub-
stantially higher compared to humans. The majority of murine 
iNKT cells are found in the liver (20–40%), whereas iNKT cells 
constitute only 1% of cells in the human liver. Moreover, the 
iNKT cell frequencies in human peripheral blood samples shows 
significant inter-donor variation (approximately 0.01–0.5% of 
T cells) which makes the study of human iNKT cell biology more 
challenging.
Contribution to Gut and Joint Disease
Considering the ability of iNKT cells to produce copious amounts 
of immunomodulatory cytokines, several studies have assessed 
the capacity of iNKT  cells to modulate autoimmune diseases 
(50–54). Some have shown that activation of iNKT  cells can 
protect from joint inflammation, while others mentioned exacer-
bation of disease (2, 35, 52–58). In TNFΔARE/+ mice, a TNF-driven 
SpA-like animal model for combined gut and joint inflammation, 
iNKT cells can dampen arthritis and ileitis by producing immu-
nomodulatory cytokines after activation by TNF-driven CD1dhigh 
dendritic cells (DCs). Interestingly, the frequency of the latter cell 
population is increased in synovial fluid from SpA patients (52). 
This example, next to evidence from an iNKT  cell-dependent 
infectious disease in  vivo model, suggests that inflammatory 
DCs can pick up antigens from the microbiota or microbial-
derived products at the intestinal draining sites and subsequently 
activate iNKT cells. Furthermore, the crosstalk between DCs and 
iNKT cells was found to be TNF-mediated (52, 59, 60). Collagen-
induced arthritis (CIA) and collagen antibody-induced arthritis 
(CAIA), two mouse models for RA, have revealed contradictive 
results. While several reports suggested a pathogenic role (55, 56, 
61, 62), iNKT cells protected from disease in a number of studies 
(54, 63, 64). Conflicting outcomes could originate from differences 
in the stimulating ligand and the time point of iNKT cell activa-
tion, since these appeared to be crucial factors (54). Regarding 
human joint disease, it has been described that RA patients have 
lower frequencies of both CD4− and CD4+ iNKT cells in periph-
eral blood compared to healthy controls, and they were skewed 
toward a Th1 phenotype (65–67) and a more restricted iNKT-TCR 
repertoire (68). There is no clear information regarding iNKT cell 
function in SpA disease so it will be of interest to study these, but 
also other innate-like T cells, in the context of joint–gut pathology 
in SpA patients.
Similar to joint disease, dichotomous effects of iNKT cells were 
observed for IBD (69). In dextran sodium sulfate-induced colitis, 
a model for human UC, activation of iNKT  cells by α-GalCer 
ameliorated disease (70, 71). Adoptive transfer in iNKT deficient 
mice also had a protective role (70, 72, 73). In contrast, iNKT cells 
exacerbated inflammation in oxazolone-induced colitis, another 
UC model, as shown from results in CD1d and iNKT-deficient 
mice (74). Again it is clear that iNKT cells are involved in the 
pathogenesis, possibly even serving a dual role depending on 
the type of IBD (UC versus CD like) and the exact conditions 
of activation and further research is warranted to elucidate the 
mechanisms, ideally by using CD1d tetramer stainings. A large 
cohort of IBD patients showed that iNKT cells were decreased in 
the blood in both CD and UC compared to healthy individuals 
(75). The intestinal lamina propria of UC patients was found to 
have a strong abundance of type 2 iNKT cells that produced high 
amounts of the cytotoxic cytokine IL-13 (76, 77). Further studies 
are required to understand whether these disturbances in cell 
numbers in patients are a result of disease or whether iNKT cells 




Mucosal-associated invariant T cells are an evolutionarily highly 
conserved cell population with two defining traits: the expression 
of a semi-invariant TCR and restriction of recognizing antigens 
presented by the MHC class I-related molecule MR1. Similar to 
iNKT cells, their TCR consists of an invariant TCR α chain paired 
with a limited array of Vβ chains (Vα7.2Jα33 paired with Vβ2 or 
Vβ13 in humans and Vα19Jα33 paired with Vβ6 and Vβ8 chains 
in mice) (3). Also, MAIT cells can be stimulated by both TCR-
activation and TCR-independent signals, such as IL-18 (36, 78). In 
both humans and mice, the majority of MAIT cells in peripheral 
blood and tissues are CD4−CD8− or CD8+ (in particular, more 
CD8αα than CD8αβ), besides very few CD4-expressing cells (79). 
The development occurs in the thymus, followed by an extrathymi-
cally maturation, a process that is regulated by multiple factors, 
including MR1, commensal gut microbiota, and the transcription 
factor PLZF (80), as illustrated by their absence in MR1-deficient 
and germ-free mice (81) and their severely reduced frequency in 
PLZF-deficient mice (82).
Identifying MAIT cells in human blood and tissue can be based 
on expression of TCR Vα7.2 (TRAV1-2) combined with the NK cell 
receptor CD161 and/or IL-18Rα (CD218). However, some of these 
surrogate markers are not present throughout the whole ontogeny, 
which has challenged accurately defining the cells. Recently, the 
production of MR1 tetramers meant a major revolution in this 
field, enabling the specific detection of MAIT cells in both humans 
and mice (82, 83). This has led to increased understanding of the 
development, which in mice occurs in three stages with only stage 
3 being functionally competent. This model is largely in parallel 
with the development in humans (80). Furthermore, MR1 tetram-
ers have allowed to describe different subsets within the MAIT cell 
population (84).
Mucosal-associated invariant T cells are predominantly found 
at mucosal and epithelial barrier sites. They are most abundant in 
the gastrointestinal tract and associated organs, such as mesen-
teric lymph nodes and the liver (in the latter organ representing 
20–45% of all human T cells), but can also be found in the blood 
(1–8% of all human T  cells). However, a lot of variation exists 
in the frequency of MAIT cells among humans, with age as an 
important determining factor (84). In mice, MAIT cells have a 
much lower frequency (at least 10-fold less than in humans) but 
are also mainly found at mucosal surfaces (82, 85). Because of their 
FiGURe 1 | Role of invariant natural killer T (iNKT) and mucosal-associated invariant T (MAIT) cells in gut and joint inflammation. Upon activation, iNKT cells and 
MAIT cells rapidly produce large quantities of cytokines. This figure focuses specifically on their pro-inflammatory effects. iNKT and MAIT cells are characterized by a 
semi-invariant T cell receptor (TCR), which can detect ligands of bacterial or self-origin. These antigens are presented by monomorphic MHC class I-like molecules 
(CD1d for iNKT cells and MR1 for MAIT cells), expressed on dendritic cells (DCs). Next to this TCR-dependent stimulation, the cells can also be activated in a 
TCR-independent cytokine-induced manner, that is danger-associated molecular pattern (DAMP) or pathogen-associated molecular pattern (PAMP) mediated. 
Activation is quickly followed by production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interferon (INF)-γ, interleukin (IL)-23, IL-17, and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). Subsequently, these mediators will recruit and activate other immune cells, which may contribute to 
inflammatory diseases, such as spondyloarthritis (SpA), characterized by combined gut and joint inflammation. Contribution to inflammation may arise from impaired 
regulatory capacities (e.g., iNKT cells) or through skewing to pro-inflammatory profiles (e.g., IL-17).
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localization in close contact with the microbiota, it is believed that 
MAIT  cells serve an essential role in modulating host-microbial 
interplay (81). They recognize and can be activated by vitamin B2 
(riboflavin) metabolites, such as ribityllumazines [for example, 
5-OP-RU or 5-(2-oxopropylideamino)-6-D-ribitylaminouracil] 
and pyrimidines (80). As many vitamin biosynthetic pathways 
are restricted to bacteria and yeasts, it is believed that MAIT cells 
detect these antigens to respond toward microbial challenges.
The majority of MAIT  cells (>80%) in peripheral blood of 
healthy humans was found to produce the Th1-related cytokines 
interferon-gamma (IFN-γ) and TNF (80). Only a small fraction 
could produce IL-17A, consistent with a low expression of RORγt 
in healthy subjects. However, it seems that peripheral expansion 
and maturation is particularly important in human MAIT cells, 
illustrated by a dominant IL-17A-producing MAIT cell popula-
tion in the liver (86).
Contribution to Gut and Joint Disease
In contrast with their role as first-line responders against micro-
bial infections (87), MAIT cells are also thought to be involved 
in a number of inflammatory and autoimmune disorders. In 
many of these diseases, a reduced systemic MAIT cell frequency 
compared with healthy individuals was observed, together with 
an increased abundance at sites where inflammation occurred 
(88, 89). For instance, IBD patients were found to have decreased 
peripheral blood MAIT  cells with an enrichment in inflamed 
intestinal tissue (90, 91). In both RA (92) and AS (93, 94), there 
was a systemic decrease in MAIT cells accompanied by elevated 
cell numbers in the synovial fluid. It should be noted that in some 
of these diseases, like IBD and RA but not AS, results could be con-
founded by the use of corticosteroids as this has been associated 
with lower systemic MAIT  cell frequencies (88). Furthermore, 
the identification in these studies was based on the expression of 
surrogate markers (TCRVα7.2+CD161hi) and not MR1-tetramer 
stainings. Upon activation, CD161 can be downregulated on 
MAIT cells, which could also have influenced these results (88).
Next to changes in frequencies, there were also phenotypical 
alterations in these diseases. In IBD, MAIT cells expressed higher 
levels of activation markers such as CD69 and they produced more 
IL-17 (90, 91). UC patients showed increased IL-18 serum levels 
and interestingly, a correlation was found with CD69 expression, 
suggesting that induced IL-18 secretion could have a role in acti-
vation of MAIT cells in these patients (91). The activation status 
of MAIT cells was positively correlated with disease activity of 
AS patients (94). An upregulation of IL-17 in these cells could 
also be observed in peripheral blood of AS patients compared to 
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healthy controls, together with a lower IFNγ production (93, 94). 
Curiously, the higher proportion of IL-17+  MAIT  cells in AS 
was only seen in male patients, while no differences in other 
clinical parameters existed. Another important finding was that 
MAIT cells in synovial fluid from AS patients show even higher 
IL-17 levels than in peripheral blood (93). These results support the 
idea that MAIT cells can contribute to inflammatory diseases in 
both the gut and joint. Interestingly, an elevated IL-17 production 
by MAIT cells was not found in RA neither in peripheral blood 
nor in synovial fluid (93), suggesting a differential mechanism 
in RA and AS disease. An important role could be attributed to 
IL-7 as gut and joint tissues of AS patients contained higher IL-7 
levels than healthy controls, next to a higher IL-7R expression in 
blood-derived MAIT cells from AS patients. Furthermore, IL-7 
priming induced IL-17 production by MAIT cells and, even more 
interesting, this response was substantially higher in AS patients 
(93). Anti-TNF therapy did not affect the MAIT  cell number 
nor did it decrease production of IL-17 or IFNγ by MAIT cells, 
further underscoring the IL-23/IL-17 axis in innate-like T cells as 
a potential therapeutic target (94).
An effector role for MAIT cells in arthritis was demonstrated 
in MR1-deficient mice, after both CIA and CAIA disease induc-
tion. MR1 deficiency significantly reduced arthritis and adoptive 
transfer of MAIT cells to MR1−/− mice exacerbated arthritis in 
CAIA (95). The situation in IBD is less clear, with one report 
showing that adoptive transfer of MAIT cells in mice with TNBS-
induced colitis resulted in milder disease (96). However, caution 
should be taken in interpreting this result, since the identification 
of MAIT cells in which study was only based on Jα33 TCR, mean-
ing that also non-MAIT conventional T cells were included (88).
COnCLUSiOn
After believing for a long time that solely MHC–peptide complexes 
can be recognized by T cells, it is now known that TCRs can also 
bind (glyco)lipid, vitamin metabolites, and other non-peptidic 
antigens. These cell types include iNKT and MAIT cells, restricted 
to MHC class I-related molecules CD1d and MR1, respectively. 
Their evolutionary highly conserved nature indicates a strong 
selective pressure to be maintained in immune responses. 
Showing features of both the innate and adaptive immunity, these 
innate-like T cells act at the interface of the two systems. In this 
regard, it is not surprising that these cells, next to their distinct but 
still unclear resident role in liver tissue, are predominantly found 
at mucosal barriers, i.e., at sites where there is a close encounter 
with microorganisms. Next to direct activation by recognizing 
microbial-derived ligands via their semi-invariant TCR, they can 
also be activated indirectly (e.g., by cytokine and TLR-mediated 
signaling), upon which they respond by rapidly producing copi-
ous amounts of effector molecules as a first-line defense making 
them excellent gatekeepers against potential invasive pathogens 
(36,  97). However, innate-like T  cells show a dichotomous 
phenotype, being not only protective but they are also thought 
to be involved in a number of immune and inflammatory dis-
eases. Indeed, iNKT and MAIT cells might be skewed toward a 
predominant pro-inflammatory state in which secretion of key 
pathogenic cytokines such as IL-17 can cause tissue pathology 
(Figure  1) (26, 27). A pathological role for innate-like T  cells 
is supported by evidence from diverse experimental models, 
although some conflicting results might reflect an aberrant role 
depending on the disease phenotype, activation kinetics, and the 
background of the animals (52, 57, 95). Interestingly, SpA-like gut 
and joint pathology shown in TNF- and IL-23-dependent animal 
models, such SKG and TNFΔARE/+ mice does not develop under 
germ-free conditions (98, 99). This underscores the relevance of 
the host (immune)-microbial interplay in the induction of SpA-
like disease features. Additionally, a state of dysbiosis as discovered 
recently in SpA patients (10–12) might contribute to chronicity of 
disease by e.g., dysregulating immunomodulatory T cell function 
and cytokine (TNF and IL-17) mediated responses. Although 
one has to keep in mind that a causal relationship has not been 
proven yet, we would postulate that it takes "guts" to cause joint 
inflammation as observed in SpA pathology. However, many 
questions still need to be addressed. For example, a specific role 
for innate-like T cells in these microbiota-mediated pathological 
events clearly awaits further investigation, especially in light of 
the complexity of the human disease. Future in depth immuno-
profiling of innate-like Tcells, next to other immunomodulatory 
cells, in gut and joint tissues from SpA patients, combined with 
further exploration of their function and role in experimental 
models under different microbial conditions (e.g., conventional 
versus germ-free housing), will shed additional light on the 
precise nature of the relationship between these unconventional 
cell populations and the microbiota, and their contribution to gut 
and joint diseases.
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